Abstract
We have investigated the effect of interferon β (INFß) on the natural killer (NK) cytotoxic activity of peripheral blood mononuclear cells (PBMC) from patients with superficial and infiltrative transitional-cell carcinoma of the bladder (TCC) against both NK-sensitive and NK-resistant target cells. The normal NK activity found in PBMC from these patients can be significantly enhanced by short-term incubation (18 h) with INFß (P<0.05). The depressed NK cytotoxic activity found in PBMC from patients with infiltrative TCC can also be significantly enhanced, but not normalized, by short-term incubation with INFß (P<0.05). In kinetic studies we found that the maximal levels of the INFß-promoted cytotoxic activity against NK-sensitive and against NK-resistant target cells in PBMC from TCC patients were reached after 18 h of culture. Short-term-INFß-incubated PBMC from patients with TCC of the bladder also showed marked cytotoxic activity against NK-resistant target cells. The effector cells of the INFß-induced cytotoxic activity in PBMC from patients with TCC were CD16+ CD3− NK cells. This cytotoxic inducer effect of INFß synergized with that of interleukin-2. In conclusion, INFß can enhance the NK activity of PMBC from patients with TCC of the bladder.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alvarez-Mon M, Casas J, Laguna R, Toribio ML, Ortiz de Landazuri M, Durantez A (1986) Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL. Blood 67: 228
Bonilla F, Alvarez-Mon M, Merino F, Hera A de la, Ales JE, España P, Durantez A (1988) Interleukin 2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer 61: 629
Carballido J, Alvarez-Mon M (1991) Immunoterapia con interferon alfa 2b intravesical en neoplasias uroteliales superficiales. Bases experimentales y clínicas. Schering-Plough, Madrid
Carballido J, Alvarez-Mon M, Solovera J, Menendez-Ondina L, Durantez A (1990) Clinical signification of NK activity in patients with TCC of the bladder, J Urol 143: 29
Carballido J, Moltó L, Manzano L, Olivier C, Salmerón O, Alvarez-Mon M, (1993) Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer 72: 1743
Friedman RM (1991) Interferons. In: Immunophysiology. The role of cells and cytokines in immunity and inflammation. Oxford University Press, Oxford, p 194
Glasham RW (1990) A randomized controlled study of intravesical alpha 2b interferon in carcinoma in situ of the bladder. J Urol 144: 658
Grimm EA, Mazumder A, Zang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823
Heo DS, Whiteside TL, Kanbour A, Herberman RB (1988) Lymphocytes infiltrating human ovarian tumors. 1. Role of leu 19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol 140: 4042
Hermanek P, Sobin LH (1987) TNM classification of malignant tumors. International union against cancer, 4th edn. Springer, Berlin Heidelberg New York
Horoszewicz JS, Murphy GP (1989) An assessment of the current use of human interferons in therapy of urological cancers. J Urol 142: 1173
Kadish AS, Doyle AT, Steinhauer EH, Ghossein NA (1981) Natural cytotoxicity and interferon production in human cancer. Deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol 127: 1817
Lotze ME, Grimm EA, Mazumder A, Strauer J, Rosenberg SA (1982) Lysis of fresh and cultured autologous tumor cells by human lymphocytes cultured in T-cell growth factor. Cancer Res 41: 4420
Morales A, Ottenhof PC (1983) Clinical application of a whole blood assay for human natural killer cell activity. Cancer 52: 667
Mukherji B, Chakraborty NG, Sivanandham M (1990) T-cell clones that react against autologous human tumors. Immunol Rev 116: 35
Niijima T, et al. (1989) Intravesical treatment of bladder cancer with recombinant human interferon β. Cancer Immunol Immunother 30: 81
Ortaldo JR, Herberman RB (1984) Heterogeneity of natural killer cells. Annu Rev Immunol 2: 359
Paucker K, Cantell K, Henle W (1962) Quantitative studies on viral interference in suspended cells. III. Effect of interferon viruses and interferon on the growth rate of cells. Virology 17: 324
Raghavan D, Shipley WU, Garnick MB, Russell PJ, Richie PJ (1990) Biology and management of bladder cancer. N Engl J Med 322: 1129
Rosenberg SA, Lotze MT, Muul LM, et al. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin 2 or high doses of interleukin 2 alone. N Engl J Med 316: 889
Sancho L, de la Hera A, Casas J, Vaquer S, Martinez-A C, Alvarez-Mon M (1991) Two different maturational stages of natural killer lymphocytes in human newborn infants. J Pediatr 119: 446
Vaquer S, de la Hera A, Jordá J, Martinez-A C, Escudero M, Alvarez-Mon M (1987) Diminished natural killer activity in pregnancy: modulation by interleukin 2 and interferon gamma. Scand J Immunol 26: 691
Witjes JA, Debrugne FMJ (1991) Optimal management of superficial bladder cancer. Eur J Cancer 27: 330
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moltó, L., Carballido, J., Manzano, L. et al. Interferon β enhances the natural killer activity of patients with bladder carcinoma. Cancer Immunol Immunother 38, 406–410 (1994). https://doi.org/10.1007/BF01517211
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01517211